BridgeBio Pharma Income from Continuous Operations 2018-2024 | BBIO
BridgeBio Pharma income from continuous operations from 2018 to 2024. Income from continuous operations can be defined as a company's total income or loss before discontinued operations, extraordinary items, preferred stock dividends and accounting change
BridgeBio Pharma Annual Income from Continuous Operations
(Millions of US $) |
| 2023 |
$-653 |
| 2022 |
$-485 |
| 2021 |
$-586 |
| 2020 |
$-505 |
| 2019 |
$-289 |
| 2018 |
$-169 |
| 2017 |
$-44 |
BridgeBio Pharma Quarterly Income from Continuous Operations
(Millions of US $) |
| 2024-09-30 |
$-164 |
| 2024-06-30 |
$-76 |
| 2024-03-31 |
$-36 |
| 2023-12-31 |
$-170 |
| 2023-09-30 |
$-179 |
| 2023-06-30 |
$-161 |
| 2023-03-31 |
$-143 |
| 2022-12-31 |
$-141 |
| 2022-09-30 |
$-140 |
| 2022-06-30 |
$-3 |
| 2022-03-31 |
$-201 |
| 2021-12-31 |
$-152 |
| 2021-09-30 |
$-161 |
| 2021-06-30 |
$-102 |
| 2021-03-31 |
$-171 |
| 2020-12-31 |
$-135 |
| 2020-09-30 |
$-130 |
| 2020-06-30 |
$-136 |
| 2020-03-31 |
$-104 |
| 2019-12-31 |
$-84 |
| 2019-09-30 |
$-61 |
| 2019-06-30 |
$-74 |
| 2019-03-31 |
$-69 |
| 2018-12-31 |
|
| 2018-09-30 |
$-42 |
| 2017-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$4.260B |
$0.009B |
|
BridgeBio Pharma Inc. discovers, develops and innovates drugs for genetic diseases. The Company's product platform consists of Mendelian, Oncology and Gene therapy. Its product pipeline includes BBP-265, BBP-831, BBP-631 and BBP-454 which are in clinical stage. BridgeBio Pharma Inc. is based in CA, United States.
|
